CrossBridge Bio raised $10M in seed financing led by TMC Venture Fund and CE-Ventures to advance the development of next-generation dual-payload ADC therapies.
CrossBridge Bio raised $10M in seed financing led by TMC Venture Fund and CE-Ventures to advance the development of next-generation dual-payload ADC therapies.
11/04/24, 1:06 PM
Location
houstonMoney raised
$10 million
Industry
therapeutics
biotechnology
health care
Round Type
seed
Investors
Linden Lake Labs, Alexandria Venture Investments, Portal Innovations, Ce Ventures, Tmc Venture Fund
CrossBridge Bio, a biotechnology company, has secured $10 million in seed financing. The funds will support the development of their lead program and expand their pipeline of novel ADC programs targeting cancer therapies.